• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

切除的胰腺腺癌的微观切缘及治疗失败模式

Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma.

作者信息

Gnerlich Jennifer L, Luka Samuel R, Deshpande Anjali D, Dubray Bernard J, Weir Joshua S, Carpenter Danielle H, Brunt Elizabeth M, Strasberg Steven M, Hawkins William G, Linehan David C

机构信息

Department of Surgery, Washington University School of Medicine, St Louis, Missouri 63110, USA.

出版信息

Arch Surg. 2012 Aug;147(8):753-60. doi: 10.1001/archsurg.2012.1126.

DOI:10.1001/archsurg.2012.1126
PMID:22911074
Abstract

OBJECTIVE

To correlate microscopic margin status with survival and local control in a large cohort of patients from a high-volume pancreatic cancer center.

DESIGN

Retrospective database review. A uniform procedure for margin analysis was used with 4-color inking (neck, portal vein groove, uncinate, and posterior pancreatic margin) by the surgeon in the operating room.

SETTING

A tertiary care hospital.

PATIENTS

We reviewed patients who underwent pancreaticoduodenectomy between September 1, 1997, and December 31, 2008, from a prospective, institutional database.

MAIN OUTCOME MEASURES

Using Cox regression models, we identified pathologic characteristics associated with local recurrence (LR) after controlling for potential confounding variables. Overall and LR-free survival curves were generated by the Kaplan-Meier method.

RESULTS

Of 285 patients who underwent pancreaticoduodenectomy for pancreatic adenocarcinoma, 97 (34.0%) had 1 or more positive microscopic margins (uncinate, 16.5%; portal vein groove, 8.8%; neck, 7.7%; and posterior, 10.5%). A total of 198 patients (69.5%) recurred, with the first site of failure being LR only in 47 (23.7%), local plus distant recurrence in 42 (21.2%), and distant recurrence only in 109 (55.1%). Patients with LR only were significantly more likely to have lymph node involvement (adjusted hazard ratio, 2.66; 95% CI, 1.25-5.63) or a positive posterior margin (adjusted hazard ratio, 4.27; 95% CI, 2.07-8.81). Patients with a positive posterior margin had significantly poorer LR-free survival with (P < .001) or without (P = .01) lymph node involvement.

CONCLUSIONS

When systematically assessed, the incidence of positive microscopic margins is high. Positive posterior margins and lymph node involvement were each independently and significantly associated with LR.

摘要

目的

在一个来自大型胰腺癌中心的大量患者队列中,将显微镜下切缘状态与生存及局部控制情况进行关联分析。

设计

回顾性数据库分析。采用统一的切缘分析程序,由外科医生在手术室进行四色标记(胰颈、门静脉沟、钩突和胰腺后缘)。

地点

一家三级医疗中心。

患者

我们从一个前瞻性的机构数据库中回顾了1997年9月1日至2008年12月31日期间接受胰十二指肠切除术的患者。

主要观察指标

使用Cox回归模型,在控制潜在混杂变量后,确定与局部复发(LR)相关的病理特征。采用Kaplan-Meier法生成总生存曲线和无局部复发生存曲线。

结果

在285例行胰十二指肠切除术的胰腺腺癌患者中,97例(34.0%)有1个或更多显微镜下阳性切缘(钩突,16.5%;门静脉沟,8.8%;胰颈,7.7%;胰腺后缘,10.5%)。共有198例患者(69.5%)复发,首次复发部位仅为局部复发的有47例(23.7%),局部加远处复发的有42例(21.2%),仅远处复发的有109例(55.1%)。仅局部复发的患者更有可能出现淋巴结受累(校正风险比,2.66;95%可信区间,1.25 - 5.63)或胰腺后缘阳性(校正风险比,4.27;95%可信区间,2.07 - 8.81)。无论有无淋巴结受累,胰腺后缘阳性的患者无局部复发生存期均显著较差(有淋巴结受累时P < .001,无淋巴结受累时P = .01)。

结论

当进行系统评估时,显微镜下阳性切缘的发生率较高。胰腺后缘阳性和淋巴结受累均各自独立且显著地与局部复发相关。

相似文献

1
Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma.切除的胰腺腺癌的微观切缘及治疗失败模式
Arch Surg. 2012 Aug;147(8):753-60. doi: 10.1001/archsurg.2012.1126.
2
Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma.淋巴结转移率是胰腺导管腺癌的一个重要预后因素。
Eur J Surg Oncol. 2012 Apr;38(4):333-9. doi: 10.1016/j.ejso.2011.12.020. Epub 2012 Feb 7.
3
Accuracy of staging node-negative pancreas cancer: a potential quality measure.淋巴结阴性胰腺癌分期的准确性:一项潜在的质量指标。
Arch Surg. 2007 Aug;142(8):767-723; discussion 773-4. doi: 10.1001/archsurg.142.8.767.
4
Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer.医院手术量对胰腺癌胰十二指肠切除术后切缘状态的影响。
J Am Coll Surg. 2008 Oct;207(4):510-9. doi: 10.1016/j.jamcollsurg.2008.04.033. Epub 2008 Jun 30.
5
Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.切除状态对胰腺癌胰十二指肠切除术后复发模式及生存的影响。
Ann Surg. 2007 Jul;246(1):52-60. doi: 10.1097/01.sla.0000259391.84304.2b.
6
Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.术前血清C反应蛋白水平和术后淋巴结比率是胰腺导管腺癌胰十二指肠切除术后生存的重要预测指标。
JOP. 2012 Mar 10;13(2):199-204.
7
Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients.胰十二指肠切除术治疗胰腺腺癌时术中切缘分析的价值:1399例患者的多中心分析
Ann Surg. 2014 Sep;260(3):494-501; discussion 501-3. doi: 10.1097/SLA.0000000000000890.
8
High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.在根治性前列腺切除术后,切缘阳性的高级别 Gleason 分级癌预示着生化失败,并且可能指导辅助放疗。
BJU Int. 2012 Jun;109(12):1794-800. doi: 10.1111/j.1464-410X.2011.10572.x. Epub 2011 Oct 12.
9
Resectable adenocarcinomas in the pancreatic head: the retroperitoneal resection margin is an independent prognostic factor.胰头可切除腺癌:腹膜后切缘是一个独立的预后因素。
BMC Cancer. 2008 Jan 14;8:5. doi: 10.1186/1471-2407-8-5.
10
Clinical significance of portal-superior mesenteric vein resection in pancreatoduodenectomy for pancreatic head cancer.胰头癌胰十二指肠切除术中门静脉-肠系膜上静脉切除的临床意义。
Pancreas. 2012 Jan;41(1):102-6. doi: 10.1097/MPA.0b013e318221c595.

引用本文的文献

1
Great Debate: Chasing Intraoperative Neck Margins During Pancreatoduodenectomy-Beneficial or Not?大辩论:胰十二指肠切除术中追踪术中颈部切缘——是否有益?
Ann Surg Oncol. 2025 Jun 12. doi: 10.1245/s10434-025-17550-z.
2
A risk score system including CT features for predicting early recurrence of resectable pancreatic ductal adenocarcinoma after radical resection: a dual-center retrospective study.一种包含CT特征的风险评分系统用于预测可切除胰腺导管腺癌根治性切除术后的早期复发:一项双中心回顾性研究
Eur Radiol. 2025 May 2. doi: 10.1007/s00330-025-11632-y.
3
Preoperative assessment of pancreatic cancer with [Ga]Ga-DOTA-FAPI-04 PET/MR versus [F]-FDG PET/CT plus contrast-enhanced CT: a prospective preliminary study.
[镓]Ga-DOTA-FAPI-04 PET/MR与[氟]F-FDG PET/CT联合增强CT对胰腺癌的术前评估:一项前瞻性初步研究。
Eur J Nucl Med Mol Imaging. 2025 Feb;52(3):1017-1027. doi: 10.1007/s00259-024-06943-z. Epub 2024 Nov 7.
4
Comparing oncologic and surgical outcomes of robotic and laparoscopic distal pancreatectomy: a propensity-matched analysis.比较机器人和腹腔镜胰体尾切除术的肿瘤学和手术结果:倾向匹配分析。
Surg Endosc. 2024 Oct;38(10):5678-5685. doi: 10.1007/s00464-024-11147-5. Epub 2024 Aug 12.
5
Disparities in neoadjuvant chemotherapy for pancreatic adenocarcinoma with vascular involvement.伴有血管侵犯的胰腺腺癌新辅助化疗的差异
Surg Open Sci. 2024 Jun 18;20:101-105. doi: 10.1016/j.sopen.2024.06.003. eCollection 2024 Aug.
6
Resection Margin Status and Long-Term Outcomes after Pancreaticoduodenectomy for Ductal Adenocarcinoma: A Tertiary Referral Center Analysis.胰十二指肠切除术治疗导管腺癌后的切缘状态与长期预后:一项三级转诊中心分析
Cancers (Basel). 2024 Jun 26;16(13):2347. doi: 10.3390/cancers16132347.
7
The impact of vascular margin invasion on local recurrence after pancreatoduodenectomy in pancreatic adenocarcinoma.胰腺癌胰十二指肠切除术后血管切缘侵犯对局部复发的影响。
Langenbecks Arch Surg. 2024 Apr 12;409(1):122. doi: 10.1007/s00423-024-03301-3.
8
Impact and optimal timing of local therapy addition in borderline resectable or locally advanced pancreatic cancer after FOLFIRINOX chemotherapy.在FOLFIRINOX化疗后,局部治疗添加至可切除边缘或局部晚期胰腺癌中的影响及最佳时机
Clin Transl Radiat Oncol. 2024 Jan 24;45:100732. doi: 10.1016/j.ctro.2024.100732. eCollection 2024 Mar.
9
NOXA Accentuates Apoptosis Induction by a Novel Histone Deacetylase Inhibitor.NOXA增强新型组蛋白去乙酰化酶抑制剂诱导的细胞凋亡。
Cancers (Basel). 2023 Jul 17;15(14):3650. doi: 10.3390/cancers15143650.
10
Current Treatment of Potentially Resectable Pancreatic Ductal Adenocarcinoma: A Medical Oncologist's Perspective.潜在可切除性胰腺导管腺癌的当前治疗:肿瘤内科医生的视角。
Cancer Control. 2023 Jan-Dec;30:10732748231173212. doi: 10.1177/10732748231173212.